Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide

European Journal of Gynaecological Oncology

Volumn 17, Issue 2, 1996, Pages 114-122

  Meden, H ^a   Meissner O ^a   Conrad, A ^a   Kuhn, W ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Chemotherapy; Emesis; Nausea; Ondansetron; Ovarian cancer

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC METAL COMPLEX; BROMAZEPAM; CARBOPLATIN; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; ONDANSETRON;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; OVARY CANCER; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BROMAZEPAM; CISPLATIN; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROLYTES; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; ONDANSETRON; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; VOMITING;

EID: 0029935426     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Coates A., Abraham S., Kaye S.B., Sowerbutts T., Frewin C., Fox R. M. et al.: "On the receiving end - patients' perception on the side-effects of cancer chemotheraphy". Eur. J. Cancer, 1982, 19, 203.
2. Meden H., Metz A., Monkeberg-Tun E.: "The quality of life of patients with ovarian cancer after surgery and chemotherapy". Onkologie, 1994, 17, 50.
3. Bonneterre J. , Chevallier B., Metz R., Fargeot P., Spielmann M., Tubiana-Ulin M. et al: "A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy". J. Clin. Oncol., 1990, 8, 1063.
4. Cubeddu L. X., Hoffman I. S., Fuenmayor N. T., Finn A. L.: "Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimes". J. Clin. Oncol., 1990, 8, 1721.
5. DeMulder P. H. M., Seyanaeve C., Vermorken J. B , van Liessum P. A., Mols-Jevdevic S., Allman E. L. et al.: "Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, crossover study". Ann. Intern. Med, 1990, 113, 834.
6. Grunberg S. M.: "Making chemotherapy easier". N. Engl. J. Med., 1990, 322, 846.
7. Many M., Pouillart P., Scholl S., Droz J. P. Azab M., Brion N. et al.: "Comparison of the 5-hydroxytryptamine (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis". N. Engl. J. Med., 1990, 322, 816.
8. Hainswoth J., Harvey W , Pendergrass K., Kasimins B., Oblon D., Monaghan G. et al.: "A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy". J. Clin. Oncol., 1991, 9, 721.
9. Hersketh P. J., Gandara D.: "Serotonin antagonists: a new class of antiemetic agents". J. Natl. Cancer Inst., 1991, 83, 613:
10. Levitt M., Warr D., Yelle L., Rayner H. L., Lofters W. S., Perrault D J., Wilson K. S. et al.: "Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophospamide, methotrexate, and fluoruracil". N Engl. J. Med., 1993, 328, 1081.
11. Bremer K , Uhlenbusch R.: "Vergleich der antiemetischen Wirksamkeit von Granisetron und Alizaprid plus Dexamethason bei Zytostatikatherapie". Dtsch. Med. Wschr., 1991, 116, 1817.
12. Gralla, R J.: "An outline of antiemetic treatment". Eur. J. Cancer Clin. Oncol., 1989, 26, 7.
13. Alberts D. S., Green S. J., Hannigan E. V.: "Improved efficacy of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Preliminary report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV suboptimal ovarian cancer". Proc. ASCO, 1989, 8, 151 (abst.).
14. Pater J.: "Cyclophosphamide/cisplatin versu cyclophosphamide/carboplatin in macroscopic residual ovarian cancer. Initial results of a National Cancer Institute of Canada Clinical Trials Group Trial". Proc. ASCO, 1990, 9, 155 (abst.).
15. Joss R.A., Brand B. C. Buser K. S., Cerny T.: "The symptomatic control of cytostatic drug-induced emesis. A recent history and review". Eur. J. Cancer, 1990, 26, 2.
16. Allan S. G., Cornbleet M. A., Warrington P. S., Golland I. M., Leonhard R. C., Smyth J. N.: "Dexamethasone and high dose metoclopramide: Efficacy in controlling cisplatin induced nausea and vomiting". Br. Med. J., 1984, 289, 878.
17. Kris M. G., Gralla R. J., Tyson L. B., Clark R. A., Groshen S.: "Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients". Cancer, 1985, 55, 527.
18. Grunberg S. M., Akerley W. A., Krailo M. D., Johnson K. B., Baker C. R., Cariffe P. A.: "Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis". Cancer Invest., 1986, 4, 379.
19. Roila F., Tonato M., Basurto C., Bella M., Oassalacqua R., Morsia D. et al.: "Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Reserach". J. Clin. Oncol., 1987, 5, 141.
20. Kris M. G., Gralla R. J., Clark R. A., Tyson L. B , Groshen S.: "Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized triait". Cancer, 1987, 60, 2816.
21. Butler A., Hill J. M., Ireland S. J., Jordan C. J., Tyers M. B.: "Pharmacological properties of GR38032F: a novel antagonist at 5-HT; receptors". J. Clin. Pharmacol., 1988, 94, 397.
22. Tyers M B.: "Pharmacology and preclinical antiemetic properties, of ondansetron". Semin. Oncol., 1992, 49, 109.
23. Smith D. B., Rusting, J., Howells N., Lambert H. E., McQuade W.: "A phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer. The North Thames Ovary Group". Ann. Oncol., 1991, 22, 607.
24. Pinkerton C. R., Williams D., Wooton C., Meller St., McElwain T. J.: "5-HT antagonist ondansetron is an effective outpatient antiemetic in cancer treatment". Arch. Dis. Child., 1990, 65, 822.
25. Harvey V. J., Evans B. D., Mitchell P. L., Mek D., Neave L. M., Langley G. B. et al.: "Reduction of carboplatin induced emesis by ondansetron". Br. J. Cancer, 1991, 63, 942.
26. Suminaga M., Furue H., Taguchi T., Ota K., Niitani H., Tsukagoshi S. et al.: "Examination of inhibitory effect, safety and usefulness of SN 307 (ondansetron) administered orally for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs". Gan-To-Kagaku-Ryoho, 1992, 19, 1891.
27. Tanneberger S., Lelli G., Martoni A., Piana E., Pannuti F.: "The antiemetic efficacy and the cost-benefit ratio on ondansetron calculated with a new approach to health technology assessment (real cost-benefit index)". J. Chemother., 1992, 4, 326.
28. Fanning J., Hilgers R. D.: "Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy". Obstet. Gynecol., 1994, 83, 601.
29. Tirrozi P. L., Laszlo J.: "Optimum management of nausea and vomiting in cancer chemotherapy". Drugs, 1987, 34, 136.
30. Kales A., Bixler E. O., Soldatos C. R., Jacoby J. A., Kales J. D.: "Lorazepam: Effects on sleep and withdrawal phenomena". Pharmacology, 1986, 33, 121.
31. Campora E., Baldini E., Rubagotti A., Chiari S., Bruzzi P., Sertoli M. R. et al.: "Double-blind randomized trial of lorazepam versus placebo with methylprednisolone for control of emesis due to non-cisplatin containing chemotherapy". J. Chemotherapy, 1990, 2, 336.
32. Smith D. B., Newlands E. S., Rustin G. J. S., Begent R. H. J., Howells N., McQuade B. et al: "Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin containing chemotheraphy". Lancet, 1991, 338, 487.
33. Jones A. L., Hill A. S., Soukop M., Hutcheon A. W., Cassidy J., Kaye S. B. et al: "Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderatly emetogenic chemotherapy". Lancet, 1991, 338, 483.